Stock Analysis, Dividends, Split History

OPK / Opko Health, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,166.31
Enterprise Value ($M)2,087.64
Book Value ($M)1,810.50
Book Value / Share3.23
Price / Book1.20
NCAV ($M)-398.89
NCAV / Share-0.71
Price / NCAV-5.43
Share Statistics
Common Shares Outstanding 559,473,568
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.16
Return on Assets (ROA)-0.11
Return on Equity (ROE)-0.15
Balance Sheet (mrq) ($M)
Quick Ratio0.90
Current Ratio1.05
Income Statement (mra) ($M)
Revenue From Receipt Of Equity0.00
Sales Revenue Net1,067,503,000.00
Sales Revenue Services Net889,076,000.00
Sales Revenue Goods Net107,759,000.00
Revenue From Transfer Of Intellectual Property70,668,000.00
Operating Income-280.06
Net Income-308.87
Earnings Per Share Basic-0.55
Earnings Per Share Diluted-0.55
Earnings Per Share Basic And Diluted-0.55
Cash Flow Statement (mra) ($M)
Cash From Operations-92.08
Cash from Investing-46.67
Cash from Financing-46.67
Identifiers and Descriptors
Central Index Key (CIK)944809
Related CUSIPS
301610101 68375N903 068375N10 68375N953

Split History

Stock splits are used by Opko Health, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
OPK : Opko Health Stock Analysis and Research Report

2017-10-16 - Asif

Opko Health is a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Its diagnostics business includes BioReference Laboratories (“BioReference”), the nation’s third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform (in development). Opko Health's pharmaceutical business features Rayaldee , an FDA-approved treatment for secondary hyperparathyroidism (“SHPT”) in adults with stage 3 or 4 chronic kidney disease (“CKD”) and vitamin D insufficiency (launched in November 2016), and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO in November 2015 and pending approval for IV formulation), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clini...

Related News Stories

Menlo Stock Plunges on Phase II Chronic Cough Study Failure

2018-10-09 zacks
Menlo Therapeutics Inc. (MNLO - Free Report) announced disappointing top-line data from a mid-stage study evaluating its sole pipeline candidate, serlopitant. The phase II study — MTI-110 (TUSSIX) — was evaluating the candidate for the treatment of refractory chronic cough. (0-3)

Quest Diagnostics Buys PhenoPath, Grows in Anatomic Pathology

2018-10-02 zacks
Quest Diagnostics Incorporated (DGX - Free Report) has purchased PhenoPath, a national provider of specialized anatomic pathology (AP) and related services. The acquisition is expected to accelerate the company’s growth strategy for advanced diagnostics. However, financial terms of the deal have been kept under wraps.

Dinner And A Movie Gone Wrong - The Idea Guide

2018-09-21 seekingalpha
This week's selected long ideas range from a semiconductor giant with an attractive cyclical position to a trust with potential hidden value. (3-2)

7 Biotech Stocks to Buy Now

2018-09-19 investorplace
Now that the biotechnology sector is well on its way to bouncing back after bottoming in May 2018, investors may feel like they missed out. The fears that previously plagued biotech stocks are no longer as big a threat. The government is no longer putting companies hiking drug price in their cross-hairs, at least not for now. This favorable environment should help biotech firms carry out their plans for the rest of the year. (39-14)

Ladenburg: Near-Term Headwinds And Unsustainable Balance Sheet Engineering

2018-09-18 seekingalpha
The SEC recently leveled allegations of securities fraud against Ladenburg’s Chairman and largest holder, Phil Frost, who owns ~34% of Ladenburg’s common equity. (3-3)

CUSIP: 68375N103